JP2007534654A - 慢性閉塞性肺疾患の処置のための、α‐リポ酸を伴う少なくとも1つのグルタチオン代謝のエフェクターの使用 - Google Patents
慢性閉塞性肺疾患の処置のための、α‐リポ酸を伴う少なくとも1つのグルタチオン代謝のエフェクターの使用 Download PDFInfo
- Publication number
- JP2007534654A JP2007534654A JP2006546083A JP2006546083A JP2007534654A JP 2007534654 A JP2007534654 A JP 2007534654A JP 2006546083 A JP2006546083 A JP 2006546083A JP 2006546083 A JP2006546083 A JP 2006546083A JP 2007534654 A JP2007534654 A JP 2007534654A
- Authority
- JP
- Japan
- Prior art keywords
- lipoic acid
- salts
- thiol
- effector
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Description
α‐リポ酸とアンブキソールの組合せによる肺胞マクロファージの細胞チオール状態に対する影響
α‐リポ酸とシリビニンの組合せによる肺胞マクロファージの細胞チオール状態に対する影響
COPD患者のプライマリ肺胞マクロファージの細胞チオール状態に対するα‐リポ酸とアンブロキソールの組合せの影響
COPD患者のプライマリ肺胞マクロファージの細胞チオール状態に対するα‐リポ酸とシリビニンの組合せの影響
肺胞マクロファージの食作用能に対する影響
Claims (11)
- 慢性閉塞性肺疾患への同時的、分離的または時間段階的な細胞保護的処置のための、α‐リポ酸、この塩類、および/またはこのプロドラッグを伴う少なくとも1つのグルタチオン代謝のエフェクターの使用。
- α‐リポ酸、この塩類、および/またはこのプロドラッグのヒト患者への投与量が30〜1800mg/d、好ましくは200〜600mg/dの間にあることを特徴とする請求項1に記載の使用。
- アンブロキソール、この塩類および/またはこのプロドラッグのヒトへの投与量が患者あたり7.5〜90mg/d、好ましくは60〜75mg/dの間にあることを特徴とする請求項3に記載の使用。
- エフェクターとして、シリビニン、この塩類および/またはこのプロドラッグが用いられることを特徴とする、請求項1〜4の少なくとも1項に記載の使用。
- シリビニン、この塩類および/またはこのプロドラッグのヒトへの投与量が患者あたり20〜1600mg/d、好ましくは300〜800mg/dの間にあることを特徴とする請求項5に記載の使用。
- 薬剤が吸入、経口または非経口により投与されうることを特徴とする、請求項1〜6の少なくともいずれか1項に記載の使用。
- 薬剤が水性溶剤、安定化剤、けん濁剤、分散剤、湿潤剤の群から選択される添加剤をさらに含有することを特徴とする、請求項1〜7の少なくともいずれか1項に記載の使用。
- 薬剤がエアゾール、溶液、顆粒、粉末、エマルション、タブレットおよび/またはフィルムタブレットの形態を有することを特徴とする、請求項1〜8の少なくともいずれか1項に記載の使用。
- グルタチオン代謝のエフェクターおよびα‐リポ酸、この塩類および/またはこのプロドラッグが、1つの組成にて存在することを特徴とする、請求項1〜9の少なくともいずれか1項に記載の使用。
- グルタチオン代謝のエフェクターおよびα‐リポ酸、この塩類および/またはこのプロドラッグが、別個の組成にて存在することことを特徴とする、請求項1〜10の少なくともいずれか1項に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10360954.7 | 2003-12-23 | ||
DE10360954A DE10360954B3 (de) | 2003-12-23 | 2003-12-23 | Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen |
PCT/EP2004/014687 WO2005063234A2 (de) | 2003-12-23 | 2004-12-23 | VERWENDUNG EINES EFFEKTOR DES GLUTATHIONMETABOLISMUS ZUSAMMEN MIT α-LIPONSÄURE ZUR BEHANDLUNG VON LUNGENERKRANKUNGEN |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007534654A true JP2007534654A (ja) | 2007-11-29 |
JP4838728B2 JP4838728B2 (ja) | 2011-12-14 |
Family
ID=34716197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006546083A Expired - Fee Related JP4838728B2 (ja) | 2003-12-23 | 2004-12-23 | 慢性閉塞性肺疾患の処置のための、α‐リポ酸を伴う少なくとも1つのグルタチオン代謝のエフェクターの使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070212339A1 (ja) |
EP (1) | EP1699451B1 (ja) |
JP (1) | JP4838728B2 (ja) |
AT (1) | ATE374608T1 (ja) |
DE (2) | DE10360954B3 (ja) |
ES (1) | ES2294567T3 (ja) |
WO (1) | WO2005063234A2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9084803B2 (en) | 2007-06-29 | 2015-07-21 | Board Of Trustees Of Northern Illinois University | Therapeutic uses of glutathione mimics |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3537656A1 (de) * | 1984-11-22 | 1986-05-22 | Dr. Madaus GmbH & Co, 5000 Köln | Verfahren zur herstellung von isosilybinfreiem silibinin und arzneimittel, enthaltend silibinin |
US5972993A (en) * | 1998-03-20 | 1999-10-26 | Avon Products, Inc. | Composition and method for treating rosacea and sensitive skin with free radical scavengers |
US6262019B1 (en) * | 1998-04-30 | 2001-07-17 | Vit-Immune, L. C. | Method of treatment of glutathione deficient mammals |
WO2001068069A2 (en) * | 2000-03-15 | 2001-09-20 | King's College London | Pharmaceutical composition comprising paracetamol |
US20020002136A1 (en) * | 2000-06-28 | 2002-01-03 | Hebert Rolland F. | Salts of glutathione |
US6495170B1 (en) * | 2000-08-16 | 2002-12-17 | N. V. Nutricia | Method of increasing the presence of glutathione in cells |
DE10125882B4 (de) * | 2001-05-28 | 2007-03-29 | Esparma Gmbh | Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus |
DE10125883A1 (de) * | 2001-05-28 | 2002-12-12 | Serumwerk Bernburg Ag | Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie |
GB0129395D0 (en) * | 2001-12-07 | 2002-01-30 | Pfizer Ltd | Pharmaceutical combination |
DE10303229B4 (de) * | 2003-01-28 | 2007-07-26 | Keyneurotek Ag | Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen |
-
2003
- 2003-12-23 DE DE10360954A patent/DE10360954B3/de not_active Expired - Fee Related
-
2004
- 2004-12-23 ES ES04804278T patent/ES2294567T3/es active Active
- 2004-12-23 JP JP2006546083A patent/JP4838728B2/ja not_active Expired - Fee Related
- 2004-12-23 AT AT04804278T patent/ATE374608T1/de active
- 2004-12-23 EP EP04804278A patent/EP1699451B1/de not_active Not-in-force
- 2004-12-23 WO PCT/EP2004/014687 patent/WO2005063234A2/de active IP Right Grant
- 2004-12-23 DE DE502004005167T patent/DE502004005167D1/de active Active
- 2004-12-23 US US10/584,072 patent/US20070212339A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070212339A1 (en) | 2007-09-13 |
WO2005063234A2 (de) | 2005-07-14 |
ATE374608T1 (de) | 2007-10-15 |
ES2294567T3 (es) | 2008-04-01 |
EP1699451B1 (de) | 2007-10-03 |
DE502004005167D1 (de) | 2007-11-15 |
EP1699451A2 (de) | 2006-09-13 |
WO2005063234A3 (de) | 2005-09-22 |
JP4838728B2 (ja) | 2011-12-14 |
DE10360954B3 (de) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2741439T3 (es) | Compuestos aromáticos sustituidos | |
AU2008317965B2 (en) | Osmolyte-containing preparation for use in case of dry mucous membranes | |
KR100264348B1 (ko) | 항-죽종형성제로서 네비볼롤을 함유하는 조성물 | |
WO2018215795A2 (en) | Senolytic compounds | |
EP3116511B1 (en) | Compositions of selenoorganic compounds and methods of use thereof | |
CN105687199A (zh) | 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂 | |
KR20080113409A (ko) | 티오레독신 산생 촉진제 | |
JP4377692B2 (ja) | ClC−2チャンネルオープナーを含む医薬組成物 | |
WO2007143724A2 (en) | Compositions and methods to enhance reverse cholesterol transport | |
JP6826038B2 (ja) | 新規モノチオール粘液溶解剤 | |
KR20150120424A (ko) | 백혈병의 치료방법 및 치료용 조성물 | |
JP4737931B2 (ja) | 医薬品の製造におけるヒドロキシオレイン酸及び類似化合物の使用 | |
EP3788054B1 (en) | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | |
JP4838728B2 (ja) | 慢性閉塞性肺疾患の処置のための、α‐リポ酸を伴う少なくとも1つのグルタチオン代謝のエフェクターの使用 | |
CN101380463A (zh) | 组合物及其治疗用途 | |
EP1716860A1 (en) | Preventive and therapeutic agent for chronic obstructive pulmonary disease | |
JP4746258B2 (ja) | 薬剤 | |
DE10125883A1 (de) | Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie | |
Bocci et al. | A practical approach for restoring Homeostasis in diseases characterized by a Chronic oxidative stress | |
US10745429B2 (en) | Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | |
CN110063520A (zh) | 一种具有抗氧化功能的烟嘴 | |
US20240173314A1 (en) | Treatment of sickle cell anaemia | |
WO2021092053A1 (en) | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | |
KR20210033456A (ko) | 산딸나무 잎 추출물을 유효성분으로 함유하는 혈관신생 억제용 조성물 | |
WO1999066926A1 (en) | Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ards) and infant respiratory distress syndrome (irds) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110811 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110907 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110930 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141007 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |